ACTIVE

Hyloris Pharmaceuticals

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result
-1,2 M €
+91,6 %over 1 year
Revenue
3,8 M €
-36,0 %over 1 year
Equity
87,2 M €
-1,4 %over 1 year
Workforce
3,4 ETP
+78,9 %over 1 year

Identity

Source · BCE/KBO

Hyloris Pharmaceuticals is a Public limited company incorporated in 2017. Its main activity is: Activities of holding companies. Its registered office is in Liège. It employs on average 3,4 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0674.494.151
Incorporation
10/04/2017
Legal form
Public limited company
Registered office
Boulevard de Patience et Beaujonc 3 box 1
4000 Liège · WallonieSee on map
Contributed capital
121 653 449,00 €
Latest accounts
31/12/2025
Average workforce
3,4 ETP
Joint committees (1)
  • 207
Signals
Solid equityLow riskGood liquidityHealthy social debtsHigh revenue

Financials

Source · NBB, 14 filings

Trend over 8 financial years

20252024202320222021
Income statement
Revenue3,8 M €6 M €1,1 M €1,2 M €2,8 M €
EBITDA-2,1 M €-4,1 M €-2,1 M €-2,5 M €-7,6 M €
Operating result-1,8 M €-4,6 M €-2,1 M €-2,5 M €-7,6 M €
Net result-1,2 M €-14,4 M €-3,4 M €-903,4 k €-7,7 M €
Balance sheet
Equity87,2 M €88,4 M €102,8 M €106,3 M €89,4 M €
Total assets101,5 M €95,7 M €114,7 M €117,8 M €105,8 M €
Cash11,7 M €22,4 M €18,8 M €4,6 M €21,7 M €
Debts14,3 M €6,9 M €10,9 M €11,5 M €14,9 M €
Other
Workforce3,4 ETP1,9 ETP2,5 ETP0,9 ETP–

Valuation

Indicative valuation

As an indication, this company is worth

between 50 M€ and 100 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

7 active · 25 ended

Active mandates

BIOFINANCE CONSULTING

Director · since 10 juin 2025 · until 13 juin 2028 · 0538.900.029

Represented by Mélanie Mestdagt

Active
IRYL Partners SAS

Director · since 10 juin 2025 · until 13 juin 2028

Represented by Revital Rattenbach

Active
SYBEFICA INVEST

Director · since 10 juin 2025 · until 13 juin 2028 · 0426.332.420

Represented by Vincent Van Dessel

Active
Jacobsen Management

Managing director · since 30 septembre 2024 · until 13 juin 2028 · 0736.534.955

Represented by Thomas Jacobsen

Active
Stefan Yee

Chairman of the board of directors · since 30 septembre 2024 · until 13 juin 2028

Active
SVR Management

Managing director · since 30 septembre 2024 · until 13 juin 2028 · 0552.806.859

Represented by Stijn Van Rompay

Active
SVR Management

Director · since 30 septembre 2024 · until 13 juin 2028 · 0552.806.859

Represented by Léon Van Rompay

Active

Ended mandates

Marc Foidart

Director · since 30 septembre 2024 · until 13 juin 2028

Ended
Revital Rattenbach

Director · since 30 septembre 2024 · until 13 juin 2028

Ended
Vincent Van Dessel

Director · since 30 septembre 2024 · until 13 juin 2028

Ended
PIENTER-JAN

Director · since 08 juin 2021 · until 30 septembre 2024 · 0831.327.414

Represented by Chris Buysse

Ended

Other companies at this address

Boulevard de Patience et Beaujonc 3 4000 Liège
CompanyCBE no.
Abscint● Active
0749.828.410
AMPACIMON● Active
0827.990.317
Amyl Therapeutics● Active
0758.775.372
BECARV● Bankrupt
0840.777.885
BE.SPINE● Active
1013.110.857
CEFALY Technology● Active
0870.578.661
DERMAX● Active
0667.730.677
DIANOSIC● Active
1034.558.646
DW Cefaly Holding● Active
0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active
1023.778.481
EXO Biologics● Active
0732.982.379
ExoXpert● Active
1003.807.666
Hirundo Biosciences● Active
0681.855.065
HolyFox Invest● Active
1010.693.181
Hyloris● Active
0669.738.676
Hyloris Developments● Active
0542.737.368
Hyloris Therapeutics● Active
1025.029.385
LEGIAPARK● Active
0728.589.170
MAN & SCIENCE● Active
0837.403.770
ONCORADIOMICS● Active
0662.719.440

Full financial information

Source · NBB
202520242023202220212020
Type of accountFull modelFull modelFull modelFull modelFull modelFull model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date07/07/202604/07/202513/11/202411/07/202312/07/202206/07/2021
General meeting09/06/202610/06/202530/09/202413/06/202314/06/202208/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 14 filings
ModelClosingGeneral meetingFiledLanguageDocument
Full model31/12/202509/06/202607/07/2026FrenchPDF
Full model31/12/202410/06/202504/07/2025FrenchPDF
Consolidated accounts31/12/202410/06/202508/07/2025FrenchPDF
Full model31/12/202330/09/202413/11/2024FrenchPDF
Consolidated accounts31/12/202330/09/202408/11/2024FrenchPDF
Full model31/12/202213/06/202311/07/2023FrenchPDF
Consolidated accounts31/12/202213/06/202312/07/2023FrenchPDF
Full model31/12/202114/06/202212/07/2022FrenchPDF
Consolidated accounts31/12/202114/06/202219/07/2022FrenchPDF
Full model31/12/202008/06/202106/07/2021FrenchPDF
Consolidated accounts31/12/202008/06/202106/07/2021FrenchPDF
Full model31/12/201908/06/202030/07/2020FrenchPDF
Abridged model31/12/201812/08/201926/08/2019FrenchPDF
Abridged model31/12/201730/08/201831/08/2018FrenchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 50 M€ and 100 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

7 active · 25 ended

Active mandates

BIOFINANCE CONSULTING

Director · since 10 juin 2025 · until 13 juin 2028 · 0538.900.029

Represented by Mélanie Mestdagt

Active
IRYL Partners SAS

Director · since 10 juin 2025 · until 13 juin 2028

Represented by Revital Rattenbach

Active
SYBEFICA INVEST

Director · since 10 juin 2025 · until 13 juin 2028 · 0426.332.420

Represented by Vincent Van Dessel

Active
Jacobsen Management

Managing director · since 30 septembre 2024 · until 13 juin 2028 · 0736.534.955

Represented by Thomas Jacobsen

Active
Stefan Yee

Chairman of the board of directors · since 30 septembre 2024 · until 13 juin 2028

Active
SVR Management

Managing director · since 30 septembre 2024 · until 13 juin 2028 · 0552.806.859

Represented by Stijn Van Rompay

Active
SVR Management

Director · since 30 septembre 2024 · until 13 juin 2028 · 0552.806.859

Represented by Léon Van Rompay

Active

Ended mandates

Marc Foidart

Director · since 30 septembre 2024 · until 13 juin 2028

Ended
Revital Rattenbach

Director · since 30 septembre 2024 · until 13 juin 2028

Ended
Vincent Van Dessel

Director · since 30 septembre 2024 · until 13 juin 2028

Ended
PIENTER-JAN

Director · since 08 juin 2021 · until 30 septembre 2024 · 0831.327.414

Represented by Chris Buysse

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Other08/04/2026
    DIVERS
    PDF
  • Mandates17/12/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates21/10/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates26/09/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates05/03/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Other30/01/2025
    DIVERS
    PDF
  • Mandates06/12/2024
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates02/10/2024
    DEMISSIONS, NOMINATIONS
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-1,2 M €↑
  2. 19/11/2025
    nominationSVR Management SRL — CEO
  3. 10/06/2025
    nominationBiofinance Consulting BV — administrateur indépendant
  4. 10/06/2025
    nominationSybefica Invest BV — administrateur indépendant
  5. 10/06/2025
    nominationIRYL Partners SAS — administrateur indépendant
  6. 10/06/2025
    nominationBDO BEDRIJFSREVISOREN BV | BDO RÉVISEURS D'ENTREPRISES SRL — commissaire aux comptes
  7. 2024
    Annual accounts 2024-14,4 M €↓
  8. 30/09/2024
    reconductionSVR Management SRL — administrateur
  9. 30/09/2024
    reconductionJacobsen Management SRE — administrateur
  10. 30/09/2024
    reconductionVan Rompay Management SRL — administrateur
  11. 30/09/2024
    reconductionStefan Yee — administrateur
  12. 30/09/2024
    nominationRevital Rattenbach — administratrice indépendante
  13. 30/09/2024
    nominationMarc Foidart — administrateur indépendant
  14. 30/09/2024
    nominationVincent Van Dessel — administrateur indépendant
  15. 26/07/2024
    nominationJacobsen Management SRL — administrateur délégué (co-CEO)
  16. 26/07/2024
    unknownCarolyn Myers — administrateur non exécutif
  17. 23/04/2024
    nominationTanguy Legein — représentant permanent du commissaire
  18. 2023
    Annual accounts 2023-3,4 M €↓
  19. 2022
    Annual accounts 2022-903,4 k €↑
  20. 22/06/2022
    augmentation_capital
  21. 14/06/2022
    reconductionOlivier Declercq — commissaire
  22. 05/04/2022
    augmentation_capital
  23. 31/03/2022
    nominationCarolyn MYERS — membre d'un comité ad hoc composé de trois administrateurs indépendants
  24. 31/03/2022
    nominationJames GALE — membre d'un comité ad hoc composé de trois administrateurs indépendants
  25. 31/03/2022
    nominationChris BUYSE — membre d'un comité ad hoc composé de trois administrateurs indépendants
  26. 31/03/2022
    augmentation_capital
  27. 2021
    Annual accounts 2021-7,7 M €↓
  28. 2019
    Annual accounts 2019-435,5 k €↑
  29. 2018
    Annual accounts 2018-457,8 k €↓
  30. 2017
    Annual accounts 2017-275,4 k €
  31. 10/04/2017
    IncorporationPublic limited company